| Outcome Measures: |
Primary: Fibrinogen level reduction, Fibrinogen level reduction from baseline to the end of study (Week 8th), 8 weeks | Secondary: Change of D-dimer, Change of D-dimer from baseline to every follow-up visit, 4 weeks and 8 weeks|Change of von Willebrand Factor activity, Change of von Willebrand Factor activity from baseline to every follow-up visit., 4 weeks and 8 weeks|Change of hs-CRP level, Change of hs-CRP level from baseline to every follow-up visit., 4 weeks and 8 weeks|Change of HbA1c, Change of HbA1c from baseline to end of study (Week 8th)., 8 weeks|Liver function, Liver function (serum ALT, AST,γ-glutamyl transferase, alkaline phosphatase) at baseline and end of study (Week 8th), 8 weeks|Renal function, Renal function (serum creatinine, BUN) at baseline and end of study (Week 8th), 8 weeks|Prothrombin Time (PT), Prothrombin time from baseline to every follow-up visit, 4 weeks and 8 weeks|Activated partial thromboplastin time (aPTT), Activated partial thromboplastin time (aPTT)from baseline to every follow-up visit, 4 weeks and 8 weeks|Adverse events, Adverse events (mainly: GI bleeding, and other bleeding events) from baseline to every follow-up visit, 4 weeks and 8 weeks (during 8 weeks)|Change of Thromboxane-B2 level, Change of Thromboxane-B2 level from baseline to every follow-up visit (as an indirect indicator to assess the effect of study treatment on TxA2), 4 weeks and 8 weeks
|
